Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.47 |
| ▸ | FNTB | P49356 | 9/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258754 | 0.92 | FNTA (0.48) | FNTAFNTBCYP11B1CYP11B2MAPKAPK2 | |
| SCHEMBL7255218 | 0.90 | CYP11B1 (0.48) | FNTAFNTBCYP11B1CYP11B2PGGT1B | |
| SCHEMBL7259737 | 0.90 | FNTA (0.51) | FNTAFNTBCYP11B1CYP11B2PGGT1B | |
| SCHEMBL7258763 | 0.89 | FNTA (0.43) | FNTAFNTBCYP11B1CYP11B2MAPKAPK2 | |
| SCHEMBL7258745 | 0.86 | FNTA (0.57) | FNTAFNTBCYP11B1CYP11B2 | |
| SCHEMBL7255266 | 0.86 | CYP11B1 (0.44) | FNTAFNTBCYP11B1CYP11B2 | |
| SCHEMBL7254956 | 0.83 | CYP11B1 (0.51) | FNTAFNTBCYP11B1CYP11B2PGGT1B | |
| SCHEMBL7255356 | 0.82 | FNTA (0.49) | FNTAFNTBPGGT1BMAPKAPK2 | |
| SCHEMBL7255227 | 0.81 | CYP11B1 (0.48) | FNTAFNTBCYP11B1CYP11B2MAPKAPK2 | |
| SCHEMBL7255988 | 0.81 | CYP11B1 (0.46) | FNTAFNTBCYP11B1CYP11B2MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003099812-A1 | PHENYL-FURAN OR PHENYL-THIOPHENE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 2003-12-04 | — | — | WO | disclosed |